
|Videos|November 12, 2017
Preliminary Findings From the NCI-MATCH Trial for Mismatch Repair-Deficient Cancers
Author(s)Nilofer Azad, MD
Nilofer Azad, MD, associate professor, Johns Hopkins University, discusses preliminary results from the NCI-Match trial for nivolumab (Opdivo) in patients with mismatch repair-deficient cancers The Society for Immunotherapy of Cancer (SITC) 32<sup>nd</sup> Annual Meeting.<br />
Advertisement
Nilofer Azad, MD, associate professor, Johns Hopkins University, discusses preliminary results from the NCI-Match trial for nivolumab (Opdivo) in patients with mismatch repair-deficient cancers during The Society for Immunotherapy of Cancer (SITC) 32ndAnnual Meeting.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
4
FDA Fast-Tracks Muzastotug Combo in MSS Metastatic Colorectal Cancer
5










































